CommercialAdministrativeLow impact
06.02.29g, AlloMap™ Molecular Expression Testing for Heart Transplant Rejection (Independence Administrators)
Independence Blue Cross·Cardiology, Cardiothoracic Surgery·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Independence Administrators has reissued their policy for AlloMap™ Molecular Expression Testing for Heart Transplant Rejection under policy 06.02.29g. This is a reissue of an existing policy with no apparent changes to coverage criteria or billing requirements.
Action Required
No immediate action required. This is a policy reissue without substantive changes. Billing team should continue following existing procedures for AlloMap testing claims for heart transplant patients.